Lundbeck, founded in 1915, is the only fully integrated pharmaceutical company focusing entirely on finding new and effective therapies for central nervous system (CNS) disorders. This strategic focus allows Lundbeck to establish strong links with academics, clinicians and patients with interests in CNS disorders.

In 2002 Lundbeck has launched two new drugs: Cipralex® (escitalopram), an even more selective serotonin reuptake inhibitor (SSRI), for depression and panic disorder, and Ebixa® (memantine), being the first drug in an entirely new therapeutical class for the treatment of moderately severe to severe Alzheimers disease.

Lundbeck is truly dedicated to research & development and has a long history of creating innovative CNS therapies, using latest research and product development technologies. Lundbecks successful SSRI citalopram (Cipramil®/Seropram®/Cipram®) has driven the company amongst the European antidepressant market leaders. The launch of Lundbecks second generation SSRI, Cipralex® (escitalopram) will further secure Lundbecks position in the antidepressant market.

Since the 1950s, Lundbeck has had a strong position in the market for antipsychotic drugs and was one of the first companies to develop and market several effective antipsychotic treatments. With the development of Serdolect® (sertindole), Lundbeck also became a front-runner in the development of atypical antipsychotic drugs. Lundbeck has two other atypical antipsychotic drug candidates in its pipeline.